Skip to main content

Table 1 Baseline characteristics of SSc patients and controls

From: Impaired myocardial perfusion is associated with extracellular volume expansion, disease activity and impaired strain and strain rate in systemic sclerosis: a cardiovascular magnetic resonance study

  Controls N=17 SSc N=17 P value
Female sex, n (%) 16 (94) 16 (94) 1.00
Age, years 55 ± 9 54 ± 10 0.76
Hypertension, n (%) 1 (6) 4 (24) 0.34
Diabetes, n (%) 0 0 -
Hyperlipidaemia, n (%) 2 (12) 3 (18) 0.63
BMI, kg/m2 24 ± 4 27 ± 7 0.21
Methotrexate, n (%) N/A 5 (29) -
Chloroquine, n (%) N/A 1 (6) -
Leflunomide, n (%) N/A 1 (6) -
Prednisolone, n (%) N/A 1 (6) -
NSAID, n (%) N/A 3 (18) -
HRT/OCP 3 (18) 3 (18) 1.00
mRSS N/A 16 ± 6 -
VDAI N/A 4 (2-5) -
ESR, mm/hr (median, IQR) N/A 11 (8-15) -
CRP, mg/L (median, IQR) 1 (1-2) 6 (3-11) <0.001
Duration of SSc, years (median, IQR) N/A 13 (7-16) -
Duration of DMARDs, years (median, IQR) N/A 4 (2-5) -
  1. Continuous data are mean ± SD unless otherwise indicated.
  2. Categorical data are frequency (percent) unless otherwise indicated.
  3. BMI, body mass index; CRP, C-reactive protein; DMARD, disease modifying anti-rheumatic drug(s); ESR, erythrocyte sedimentation rate; HRT/OCP, hormone replacement therapy or oral contraceptive pill; IQR, interquartile range; mRSS, modified Rodnan skin score; NSAID, non-steroidal anti-inflammatory drug(s); SSc, systemic sclerosis; VDAI, Valentini disease activity index